



Altimune to Announce Second Quarter 2019 Financial Results on August 14

August 5, 2019

GAITHERSBURG, Md., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Altimune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, today announced that it will report financial results for the three and six months ended June 30, 2019 before the market open and host a conference call on Wednesday, August 14, 2019.

Conference Call Details

Date: Wednesday, August 14
Time: 8:30 am Eastern Time
Domestic: 877-423-9813
International: 201-689-8573
Conference ID: 13692577
Webcast: <http://public.viavid.com/index.php?id=135358>

About Altimune

Altimune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcell™), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAX™ and NasoShield™). For more information on Altimune, please visit www.altimmune.com.

Contacts:

Will Brown
Chief Financial Officer
Phone: 240-654-1450
wbrown@altimmune.com

Ashley R. Robinson
LifeSci Advisors, LLC
617-535-7742
arr@lifesciadvisors.com



Source: Altimune, Inc.